ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 616

Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects

Wendy Cai1, Cecil Chen1, Z. John Zhong1, William W. Freimuth1, William Lewis2 and David Subich3, 1Human Genome Sciences, Inc., Rockville, MD, 2Covance Clinical Research Unit, Inc., Dallas, TX, 3Covance Clinical Research Unit, Inc., Daytona Beach, FL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: B cells, belimumab, pharmacology and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: Belimumab is a recombinant, human Ig-G1λ monoclonal antibody that binds and antagonizes the biological activity of soluble B-lymphocyte stimulator protein, a member of the tumor necrosis factor ligand superfamily that promotes the survival of B lymphocytes. This study (NCT#01583530) evaluated the absolute bioavailability, PK, tolerability, and safety of belimumab (200 mg/mL) administered SC to healthy subjects as a single dose and as multiple doses up to 240 mg.

Methods: In all, 118 healthy subjects (aged 18−55 y; body weight 51−115 kg) were enrolled. Seventy-eight subjects received a single dose of belimumab 240 mg IV, or 2×120, 1×240, or 1×200 mg SC. Forty subjects received 4 weekly injections of belimumab 2×120 or 1×200 mg SC. Randomization was stratified by weight (< vs ≥ 75 kg) and, for SC administration, by injection site (abdomen vs thigh), with a target enrollment of ~50% women/treatment group. Serial blood samples were collected and the serum belimumab concentrations measured by a validated electrochemiluminescence-based assay. Belimumab PK parameters were derived by noncompartmental or compartmental analysis. 

Results: The bioavailability and PK parameters of belimumab following single IV and SC administration are summarized in the table. Following 4 weekly SC belimumab doses, bioavailability values (90% CI) were 75% (63%−89%) and 78% (67%-91%) for the 2×120- and 1×200-mg SC groups, respectively. Four subjects had persistent positive immune responses; neutralizing antibodies in these subjects were not detected and there was no apparent impact on PK. Single and multiple dosing of belimumab was generally safe and well tolerated, with no severe/serious injection-site reactions, eg, rash, edema, erythema, and pruritus.

Conclusion: Following single belimumab SC doses, bioavailability was 74%−82%, indicating that belimumab SC was well absorbed, and bioavailability was similar among the 3 SC groups. Bioavailability after 4 weekly SC doses was similar to that following single SC administration. Belimumab was generally safe and well tolerated after single and multiple SC dosing.

 

PK and Bioavailability of Belimumab

 

Parameter

Belimumab

240 mg IV

2×120 mg SC

1×240 mg SC

1×200 mg SC

No. of subjects

19

19

18

18

tmax, da

0.09 (0.05-0.30)

3.9 (0.9-9.8)

4.9 (2.9-13.9)

5.9 (1.9-13.9)

Cmax, µg/mLb

86.2 (20.2)

32.7 (29.0)

31.6 (27.9)

24.3 (40.3)

AUC0-∞, µg∙d/mLb

1030 (32.1)

788 (36.1)

812 (36.2)

612 (37.9)

t1/2,term, dc

18.2 ± 6.3

15.9 ± 5.3

18.2 ± 6.0

16.0 ± 5.1

F, %d

–

76 (64−90)

82 (70−95)

74 (60−91)

aMedian (range); bgeometric mean (coefficient of variance); cmean ± SD; dabsolute bioavailability (F) and 90% CI.

AUC0-∞, area under plasma concentration-time curve from time 0 to ∞; Cmax, maximum plasma drug concentration; tmax, time to reach maximum plasma concentration; t1/2,term, terminal half-life. 


Disclosure:

W. Cai,

HGS,

1,

HGS,

3;

C. Chen,

HGS,

1,

HGS,

3;

Z. J. Zhong,

HGS,

1,

HGS,

3;

W. W. Freimuth,

HGS,

1,

HGS,

3;

W. Lewis,
None;

D. Subich,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bioavailability-pharmacokinetics-and-safety-of-belimumab-administered-subcutaneously-in-healthy-subjects/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology